GB0700058D0 - Anti-tumor vaccine based on normal cells - Google Patents

Anti-tumor vaccine based on normal cells

Info

Publication number
GB0700058D0
GB0700058D0 GBGB0700058.1A GB0700058A GB0700058D0 GB 0700058 D0 GB0700058 D0 GB 0700058D0 GB 0700058 A GB0700058 A GB 0700058A GB 0700058 D0 GB0700058 D0 GB 0700058D0
Authority
GB
United Kingdom
Prior art keywords
normal
composition
cells
lymphoid cells
lymphocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0700058.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCANCELL APS
Original Assignee
SCANCELL APS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCANCELL APS filed Critical SCANCELL APS
Priority to GBGB0700058.1A priority Critical patent/GB0700058D0/en
Publication of GB0700058D0 publication Critical patent/GB0700058D0/en
Priority to JP2009544412A priority patent/JP5452231B2/ja
Priority to US12/522,048 priority patent/US10023839B2/en
Priority to HR20110899T priority patent/HRP20110899T1/hr
Priority to PCT/EP2008/050050 priority patent/WO2008081035A1/en
Priority to AU2008203730A priority patent/AU2008203730B2/en
Priority to DK08701232.4T priority patent/DK2102331T3/da
Priority to PT08701232T priority patent/PT2102331E/pt
Priority to PL08701232T priority patent/PL2102331T3/pl
Priority to EP08701232A priority patent/EP2102331B1/en
Priority to SI200830447T priority patent/SI2102331T1/sl
Priority to ES08701232T priority patent/ES2372713T3/es
Priority to AT08701232T priority patent/ATE522600T1/de
Priority to CY20111101112T priority patent/CY1112668T1/el
Priority to US15/707,474 priority patent/US20180036397A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB0700058.1A 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells Ceased GB0700058D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB0700058.1A GB0700058D0 (en) 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells
AT08701232T ATE522600T1 (de) 2007-01-03 2008-01-03 Anti-tumor impfstoff aus normalen chemisch modifizierten cd4+ zellen
DK08701232.4T DK2102331T3 (da) 2007-01-03 2008-01-03 Anti-tumorvaccine afledt af normale kemisk modificerede CD4 -celler
PL08701232T PL2102331T3 (pl) 2007-01-03 2008-01-03 Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
HR20110899T HRP20110899T1 (hr) 2007-01-03 2008-01-03 Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+
PCT/EP2008/050050 WO2008081035A1 (en) 2007-01-03 2008-01-03 Anti-tumor vaccine derived from normal chemically modified cells
AU2008203730A AU2008203730B2 (en) 2007-01-03 2008-01-03 Anti-tumor vaccine derived from normal chemically modified cells
JP2009544412A JP5452231B2 (ja) 2007-01-03 2008-01-03 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン
PT08701232T PT2102331E (pt) 2007-01-03 2008-01-03 Vacina antitumoral derivada de células cd4+ normais modificadas quimicamente
US12/522,048 US10023839B2 (en) 2007-01-03 2008-01-03 Anti-tumour vaccine derived from normal cells
EP08701232A EP2102331B1 (en) 2007-01-03 2008-01-03 Anti-tumor vaccine derived from normal chemically modified cd4+ cells
SI200830447T SI2102331T1 (sl) 2007-01-03 2008-01-03 Antitumorsko cepivo, izvedeno iz normalnih kemično modificiranih CD4+ celic
ES08701232T ES2372713T3 (es) 2007-01-03 2008-01-03 Vacuna antitumoral derivada de celulas cd4+ normales modificadas químicamente.
CY20111101112T CY1112668T1 (el) 2007-01-03 2011-11-17 Εμβολιο εναντι ογκων που προκυπτει απο φυσιολογικα χημικως τροποποιημενα cd4+ κυτταρα
US15/707,474 US20180036397A1 (en) 2007-01-03 2017-09-18 Anti-tumor vaccine derived from normal cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0700058.1A GB0700058D0 (en) 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells

Publications (1)

Publication Number Publication Date
GB0700058D0 true GB0700058D0 (en) 2007-02-07

Family

ID=37759205

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0700058.1A Ceased GB0700058D0 (en) 2007-01-03 2007-01-03 Anti-tumor vaccine based on normal cells

Country Status (14)

Country Link
US (2) US10023839B2 (enExample)
EP (1) EP2102331B1 (enExample)
JP (1) JP5452231B2 (enExample)
AT (1) ATE522600T1 (enExample)
AU (1) AU2008203730B2 (enExample)
CY (1) CY1112668T1 (enExample)
DK (1) DK2102331T3 (enExample)
ES (1) ES2372713T3 (enExample)
GB (1) GB0700058D0 (enExample)
HR (1) HRP20110899T1 (enExample)
PL (1) PL2102331T3 (enExample)
PT (1) PT2102331E (enExample)
SI (1) SI2102331T1 (enExample)
WO (1) WO2008081035A1 (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011421B1 (ru) * 2008-08-26 2009-02-27 Петр Генриевич ЛОХОВ Способ получения противоопухолевой вакцины
US8586359B2 (en) 2009-07-28 2013-11-19 Promising Furture, LLC Compositions and methods of preparing alloreactive cytotoxic T cells
US8666674B2 (en) 2009-07-28 2014-03-04 Promising Future, Llc Pairing processes for preparing reactive cytotoxic T cells
CN102597222B (zh) * 2009-10-27 2015-07-15 因缪尼卡姆股份公司 用于增殖抗原特异性t细胞的方法
GB201013443D0 (en) 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
US10426740B1 (en) 2010-08-18 2019-10-01 Avm Biotechnology, Llc Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
KR20230148387A (ko) 2015-05-28 2023-10-24 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
BR112017025166A2 (en) 2015-05-28 2018-07-31 Kite Pharma, Inc. Methods of Conditioning Patients for T-Cell Therapy
IL292504B2 (en) 2015-10-20 2024-01-01 Kite Pharma Inc Methods of preparing T cells for T cell therapy
US10689450B2 (en) 2016-04-01 2020-06-23 Kite Pharma, Inc BCMA binding molecules and methods of use thereof
PL3436079T3 (pl) 2016-04-01 2021-12-20 Kite Pharma, Inc. Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
PE20190356A1 (es) 2016-04-01 2019-03-07 Kite Pharma Inc Receptores quimericos y metodos de uso de los mismos
TWI785009B (zh) 2017-02-14 2022-12-01 美商凱特製藥公司 Ｃｄ７０結合分子及使用彼之方法
WO2018169922A2 (en) 2017-03-13 2018-09-20 Kite Pharma, Inc. Chimeric antigen receptors for melanoma and uses thereof
ES2954311T3 (es) 2017-04-01 2023-11-21 Avm Biotechnology Llc Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
CN110494158A (zh) 2017-04-03 2019-11-22 凯德药业股份有限公司 使用包含优化的多功能t细胞的嵌合受体t细胞进行治疗
JOP20180042A1 (ar) 2017-04-24 2019-01-30 Kite Pharma Inc نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
KR20210118479A (ko) 2017-05-26 2021-09-30 카이트 파마 인코포레이티드 배아 중간엽 전구 세포를 제조하고 사용하는 방법
WO2019055896A1 (en) 2017-09-15 2019-03-21 Kite Pharma, Inc. METHODS AND SYSTEMS FOR PERFORMING A PATIENT-CLEAN IMMUNOTHERAPY PROCEDURE WITH FOLLOW-UP OF BIOLOGICAL SAMPLE CHAIN OF CONTROL AND IDENTITY CHAIN
KR20230007557A (ko) 2017-09-22 2023-01-12 카이트 파마 인코포레이티드 키메라 폴리펩티드 및 그의 용도
CA3084470A1 (en) 2017-10-18 2019-04-25 Kite Pharma, Inc. Methods of administering chimeric antigen receptor immunotherapy
US11390655B2 (en) 2017-11-16 2022-07-19 Kite Pharma, Inc. Modified chimeric antigen receptors and methods of use
EP3740285A1 (en) 2018-01-15 2020-11-25 Pfizer Inc. Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
WO2019152957A1 (en) 2018-02-02 2019-08-08 Arizona Board Of Regents On Behalf Of Arizona State University Dna-chimeric antigen receptor t cells for immunotherapy
WO2019161271A1 (en) 2018-02-16 2019-08-22 Kite Pharma, Inc. Modified pluripotent stem cells and methods of making and use
WO2019200325A1 (en) 2018-04-12 2019-10-17 Kite Pharma, Inc. Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
EP3801572B1 (en) 2018-06-01 2024-07-03 Kite Pharma, Inc. Chimeric antigen receptor t cell therapy
EP3810780A1 (en) 2018-06-22 2021-04-28 Kite Pharma Eu B.V. Compositions and methods for making engineered t cells
KR20210038922A (ko) 2018-08-02 2021-04-08 카이트 파마 인코포레이티드 키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
EP3488851A1 (en) 2018-10-03 2019-05-29 AVM Biotechnology, LLC Immunoablative therapies
EP3632446B3 (en) 2018-10-03 2024-01-24 AVM Biotechnology, LLC Immunoablative therapies
IL283734B2 (en) 2018-12-12 2025-03-01 Kite Pharma Inc Chimeric antigen receptors and CAR-T cells and methods of use
US20220175900A1 (en) * 2019-04-12 2022-06-09 Cytovac A/S Method for preparation of cancer/testis antigen-specific t-cells
TW202108150A (zh) 2019-05-03 2021-03-01 美商凱特製藥公司 投與嵌合抗原受體免疫療法之方法
BR112021025735A2 (pt) 2019-06-21 2022-03-08 Kite Pharma Inc Receptores de tgf-ss e métodos de uso
CA3147441A1 (en) 2019-09-03 2021-03-11 Allogene Therapeutics, Inc. Methods of preparing t cells for t cell therapy
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
US12152251B2 (en) 2020-08-25 2024-11-26 Kite Pharma, Inc. T cells with improved functionality
WO2022093925A1 (en) 2020-10-28 2022-05-05 Kite Pharma, Inc. Flow cytometric method for characterization of t-cell impurities
IL303984A (en) 2020-12-24 2023-08-01 Kite Pharma Inc Chimeric antigen receptors for prostate cancer
CA3207182A1 (en) 2021-01-10 2022-07-14 Kite Pharma, Inc. T cell therapy
WO2022157288A1 (en) 2021-01-21 2022-07-28 Cytovac A/S Method for t-cell expansion and related medical applications
JP2024507199A (ja) 2021-02-20 2024-02-16 カイト ファーマ インコーポレイテッド 免疫療法を選択するための遺伝子マーカー
US12454563B2 (en) 2021-03-11 2025-10-28 Kite Pharma, Inc. Immune cell function
WO2022221126A1 (en) 2021-04-16 2022-10-20 Kite Pharma, Inc. Methods and systems for scheduling a patient-specific immunotherapy procedure
JP7688723B2 (ja) 2021-04-16 2025-06-04 カイト ファーマ インコーポレイテッド Ｔａｃｉ／ｂｃｍａ二重結合分子
US12357646B2 (en) 2021-05-14 2025-07-15 Kite Pharma, Inc. Chimeric antigen receptor T cell therapy
JP2024521756A (ja) 2021-05-24 2024-06-04 カイト ファーマ インコーポレイテッド キメラ抗原受容体
CN117730100A (zh) 2021-06-08 2024-03-19 凯德药业股份有限公司 Gpc3结合分子
WO2022269019A1 (en) 2021-06-25 2022-12-29 Cytovac A/S Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells
US20230027004A1 (en) 2021-07-01 2023-01-26 Kite Pharma, Inc. Closed-system and method for autologous and allogeneic cell therapy manufacturing
JP2024525485A (ja) 2021-07-02 2024-07-12 カイト ファーマ インコーポレイテッド 細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法
EP4376876A1 (en) 2021-07-26 2024-06-05 Kite Pharma, Inc. Split chimeric antigen receptors and methods of use
AU2022317827B2 (en) 2021-07-30 2025-12-11 Kite Pharma, Inc. Monitoring and management of cell therapy-induced toxicities
AR127745A1 (es) 2021-10-18 2024-02-28 Kite Pharma Inc Dominios de señalización para receptores quiméricos de antígenos
AU2023221839A1 (en) 2022-02-15 2024-08-22 Kite Pharma, Inc. Predicting adverse events from immunotherapy.
WO2023247324A1 (en) 2022-06-24 2023-12-28 Cytovac A/S Novel combination treatment with adoptive cellular therapy
EP4577234A1 (en) 2022-08-26 2025-07-02 Kite Pharma, Inc. Improving immune cell function
CN119997962A (zh) 2022-10-28 2025-05-13 凯德药业股份有限公司 改善免疫疗法的功效和持久应答
TW202530421A (zh) 2022-10-28 2025-08-01 美商凱特製藥公司 用於將免疫療法最佳化之因素
US20240309428A1 (en) 2023-03-17 2024-09-19 Kite Pharma, Inc. Impact of tumor microenvironment on efficacy of immunotherapy
WO2025096517A1 (en) 2023-11-01 2025-05-08 Kite Pharma, Inc. Factors for optimizing immunotherapy efficacy
WO2025174963A1 (en) 2024-02-16 2025-08-21 Kite Pharma, Inc. Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
US20250290154A1 (en) 2024-03-04 2025-09-18 Kite Pharma, Inc. Predictive markers for immunotherapy
WO2025231376A1 (en) 2024-05-03 2025-11-06 Kite Pharma, Inc. Chimeric receptors binding to cll-1 and methods of use thereof
WO2025250819A1 (en) 2024-05-31 2025-12-04 Kite Pharma, Inc. Tricistronic constructs for anti-gpc3 car

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012085A1 (en) * 2001-07-30 2003-02-13 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Antigen presenting cells, method for their preparation and their use for cancer vaccines

Also Published As

Publication number Publication date
US10023839B2 (en) 2018-07-17
JP2010514455A (ja) 2010-05-06
PT2102331E (pt) 2011-12-19
PL2102331T3 (pl) 2012-01-31
AU2008203730A1 (en) 2008-07-10
ATE522600T1 (de) 2011-09-15
DK2102331T3 (da) 2011-10-17
SI2102331T1 (sl) 2012-01-31
JP5452231B2 (ja) 2014-03-26
US20180036397A1 (en) 2018-02-08
US20100092498A1 (en) 2010-04-15
EP2102331B1 (en) 2011-08-31
CY1112668T1 (el) 2016-02-10
ES2372713T3 (es) 2012-01-25
HRP20110899T1 (hr) 2011-12-31
WO2008081035A1 (en) 2008-07-10
AU2008203730B2 (en) 2013-11-07
EP2102331A1 (en) 2009-09-23

Similar Documents

Publication Publication Date Title
GB0700058D0 (en) Anti-tumor vaccine based on normal cells
Zom et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates
Melief et al. Therapeutic cancer vaccines
Kumai et al. Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses
Krieg Development of TLR9 agonists for cancer therapy
Aranda et al. Trial Watch: Peptide vaccines in cancer therapy
Seledtsov et al. Clinically feasible approaches to potentiating cancer cell-based immunotherapies
JP2010514455A5 (enExample)
Son et al. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model
Alexandrescu et al. Immunotherapy for melanoma: current status and perspectives
MX338294B (es) Novedoso inmunotratamiento contra diversos tumores incluidos tumores neuronales y cerebrales.
EA202190587A3 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
BR112012023692A2 (pt) imunoterapias contra vários tumores, incluindo câncer gastrointestinal e gástrico
Elster et al. Dendritic cell vaccines: A review of recent developments and their potential pediatric application
CY1114912T1 (el) Εμβολιο για την προληψη της υποτροπης του καρκινου του μαστου
Liu et al. Induction on differentiation and modulation of bone marrow progenitor of dendritic cell by methionine enkephalin (MENK)
Ren et al. Therapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles)
Salem The use of dendritic cells for peptide-based vaccination in cancer immunotherapy
WO2008118369A3 (en) Methods for inducing a natural killer (nk) cell-mediated immune response and for increasing nk cell activity
JP2018522880A5 (enExample)
Öhlschläger et al. The combination of TLR‐9 adjuvantation and electroporation‐mediated delivery enhances in vivo antitumor responses after vaccination with HPV‐16 E7 encoding DNA
Masuko et al. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy
Chang et al. Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy
MX2020011793A (es) Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer.
Izgi et al. Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)